Receptors as the entry point
Cells do not respond to peptides by absorbing them wholesale. They respond through receptors - proteins embedded in the cell membrane that change shape when a specific molecule binds to them. This conformational change triggers an intracellular cascade: a chain of molecular events that ultimately alters what the cell does.
The relationship between a peptide and its receptor is specific. A peptide's three-dimensional shape must complement the receptor's binding site - the classic lock-and-key analogy. Minor structural changes in a peptide can dramatically alter whether it binds, how strongly it binds, and what effect that binding produces.
G protein-coupled receptors
Many peptides act through a family of receptors called G protein-coupled receptors (GPCRs). When a peptide binds a GPCR, the receptor activates a G protein inside the cell. The G protein then modulates the activity of enzymes or ion channels, producing effects such as changes in cyclic AMP (cAMP) levels, calcium flux, or gene transcription.
GLP-1 (glucagon-like peptide-1) receptors are GPCRs. When a GLP-1 receptor agonist binds, it activates adenylyl cyclase through a Gs protein, raising intracellular cAMP. In pancreatic beta cells, this cascade increases insulin secretion in a glucose-dependent manner. The same receptor exists in the brain, heart, and gut - which explains why GLP-1 agonists affect satiety and gastric emptying in addition to blood sugar.
Agonists, antagonists, and partial agonists
A molecule that binds a receptor and activates it is an agonist. One that binds but does not activate - and blocks other agonists from binding - is an antagonist. A partial agonist occupies the receptor and produces some activation, but less than a full agonist would.
Many synthetic peptides in research are designed as agonists of naturally occurring receptors. Some are modified analogues of the endogenous (naturally occurring) peptide with improved binding affinity, longer half-life, or altered receptor selectivity.
Downstream signalling cascades
The signal initiated at the receptor surface does not stay at the surface. It propagates through a series of intermediate proteins - kinases, phosphatases, second messengers - before reaching the nucleus or other effectors that change cellular behaviour. This amplification means a small number of occupied receptors can produce a large cellular response.
For researchers, this cascade is the object of study. Understanding which part of the cascade a peptide activates, and how that activation changes cell function in a specific tissue or model system, is the core question of most peptide research.
Selectivity and off-target effects
No peptide binds exclusively to one receptor. Related receptors with similar binding sites may also respond, producing effects that were not the primary target of the study. Understanding a peptide's selectivity profile - how strongly it binds its primary target versus related receptors - is essential context for interpreting research results.
References: Pierce KL et al. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002. Luttrell LM. Minireview: More than just a hammer. Mol Endocrinol. 2014.
Receptors as the entry point
Cells do not respond to peptides by absorbing them wholesale. They respond through receptors - proteins embedded in the cell membrane that change shape when a specific molecule binds to them. This conformational change triggers an intracellular cascade: a chain of molecular events that ultimately alters what the cell does.
The relationship between a peptide and its receptor is specific. A peptide's three-dimensional shape must complement the receptor's binding site - the classic lock-and-key analogy. Minor structural changes in a peptide can dramatically alter whether it binds, how strongly it binds, and what effect that binding produces.
G protein-coupled receptors
Many peptides act through a family of receptors called G protein-coupled receptors (GPCRs). When a peptide binds a GPCR, the receptor activates a G protein inside the cell. The G protein then modulates the activity of enzymes or ion channels, producing effects such as changes in cyclic AMP (cAMP) levels, calcium flux, or gene transcription.
GLP-1 (glucagon-like peptide-1) receptors are GPCRs. When a GLP-1 receptor agonist binds, it activates adenylyl cyclase through a Gs protein, raising intracellular cAMP. In pancreatic beta cells, this cascade increases insulin secretion in a glucose-dependent manner. The same receptor exists in the brain, heart, and gut - which explains why GLP-1 agonists affect satiety and gastric emptying in addition to blood sugar.
Agonists, antagonists, and partial agonists
A molecule that binds a receptor and activates it is an agonist. One that binds but does not activate - and blocks other agonists from binding - is an antagonist. A partial agonist occupies the receptor and produces some activation, but less than a full agonist would.
Many synthetic peptides in research are designed as agonists of naturally occurring receptors. Some are modified analogues of the endogenous (naturally occurring) peptide with improved binding affinity, longer half-life, or altered receptor selectivity.
Downstream signalling cascades
The signal initiated at the receptor surface does not stay at the surface. It propagates through a series of intermediate proteins - kinases, phosphatases, second messengers - before reaching the nucleus or other effectors that change cellular behaviour. This amplification means a small number of occupied receptors can produce a large cellular response.
For researchers, this cascade is the object of study. Understanding which part of the cascade a peptide activates, and how that activation changes cell function in a specific tissue or model system, is the core question of most peptide research.
Selectivity and off-target effects
No peptide binds exclusively to one receptor. Related receptors with similar binding sites may also respond, producing effects that were not the primary target of the study. Understanding a peptide's selectivity profile - how strongly it binds its primary target versus related receptors - is essential context for interpreting research results.
References: Pierce KL et al. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002. Luttrell LM. Minireview: More than just a hammer. Mol Endocrinol. 2014.
